Attached files
| file | filename |
|---|---|
| EX-32.1 - EX-32.1 - Adamas Pharmaceuticals Inc | adms10k2019ex321.htm |
| EX-31.2 - EX-31.2 - Adamas Pharmaceuticals Inc | adms10k2019ex312.htm |
| EX-31.1 - EX-31.1 - Adamas Pharmaceuticals Inc | adms10k2019ex311.htm |
| EX-21.1 - EX-21.1 - Adamas Pharmaceuticals Inc | adms10k2019ex211.htm |
| EX-10.41 - EX-10.41 - Adamas Pharmaceuticals Inc | adms10k2019ex1041.htm |
| EX-10.37 - EX-10.37 - Adamas Pharmaceuticals Inc | adms10k2019ex1037.htm |
| EX-10.6 - EX-10.6 - Adamas Pharmaceuticals Inc | adms10k2019ex106.htm |
| EX-4.4 - EX-4.4 - Adamas Pharmaceuticals Inc | adms10k2019ex44.htm |
| 10-K - 10-K - Adamas Pharmaceuticals Inc | adms-20191231.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (No. 333-234570) and Form S-8 (Nos. 333-230058, 333-223147, 333-216313, 333-210255, 333-202467 and 333-195384) of Adamas Pharmaceuticals, Inc. of our report dated February 25, 2020 relating to the financial statements and the effectiveness of internal control over financial reporting, which appears in this Form 10-K.
/s/ PricewaterhouseCoopers LLP
San Jose, California
February 25, 2020